摘要
目的:观察奥曲肽保护急性胰腺炎患者肠黏膜屏障功能的疗效和安全性。方法:64例急性胰腺炎患者随机分为奥曲肽组和对照组各32例。两组均予以禁食禁饮、胃肠减压、解痉镇痛、预防感染和静脉营养支持等对症治疗,奥曲肽组在此基础上加用奥曲肽100μg,ih,q8h,连用1周。观察两组患者治疗前后血清内毒素、D-乳酸和肿瘤坏死因子-α(TNF-α)水平的变化,比较两组临床疗效和药品不良反应。结果:治疗1周后,两组患者血清内毒素、D-乳酸和TNF-α水平均较治疗前明显下降(P<0.05或0.01),且奥曲肽组下降值明显大于对照组(P<0.05);奥曲肽组临床总有效率明显高于对照组(P<0.05)。对照组和奥曲肽组治疗期间发生不良反应2例和5例,症状均较轻,两组比较,差异无统计学意义(P>0.05)。结论:奥曲肽治疗急性胰腺炎有效,尤其是轻型患者,能降低血清内毒素、D-乳酸和TNF-α水平,保护肠黏膜屏障功能,安全性好。
Objective：：To discuss the protection effect of octreotide on intestinal mucosal barrier function of acute pancreatitis （AP） patients. Methods：64 cases of acute pancreatitis （AP） patients were randomly divided into octreotide group and controlled group. The patients in the two groups were given symptomatic treatment like fasting and water deprivation, gastrointestinal decompression, antispasmodic and analgesic, infection prevention （IP）, parenteral nutritional support, etc. The patients in octreotide group were given octreotide （100 μg） by subcutaneous injection once every 8 hours for 1 week, and the patients in the controlled group were given the same medical treatment except octreotide. The changes of toxin, D lactic acid, and TNF α in the serum of the patients in the two groups were observed before and after medical treatment.Results：After 1 week’s medical treatment, toxin, D lactic acid, and TNF α levels in the serum of the patients in the two groups declined more obviously than before （P〈0.05or P〈0.01）, and the declining rate in octreotide group was much higher than that in the controlled group （P〈0.05）; meanwhile, the total curative efficiency in octreotide group was much higher than that in the controlled group. 2 or 5 cases of ADRs appeared in the control group and octreotide group during the medical treatment with no statistical differences after comparison （P〉0.05）. Conclusion：Octreotide had its reliable effect on acute pancreatitis （AP）, especially in mild case patients, whose mechanism of action had close effect on lowering the toxin, D lactic acid and TNF α levels in serum, and protecting the function of intestinal mucosal barrier.
出处
《药物流行病学杂志》
CAS
2014年第4期218-220,共3页
Chinese Journal of Pharmacoepidemiology
